H.C. Wainwright reiterates Buy on BridgeBio stock on trial data

H.C. Wainwright has reaffirmed its Buy rating for BridgeBio Pharma (NASDAQ:BBIO) stock, maintaining a $120 price target, following promising data from the company's Phase 3 ATTRibute-CM study. The study, presented at the European Society of Cardiology Congress 2026 in Munich, Germany, focused on acoramidis, a near-complete transthyretin stabilizer.

BridgeBio reported that 54% of acoramidis-treated patients showed clinically meaningful improvement in left ventricular systolic function at Month 30, compared to 20% of placebo-treated patients. At Month 42, this percentage increased to 53%. Another analysis suggested that long-term acoramidis treatment led to significant improvement in 34% of acoramidis-treated patients, versus 9% of placebo-treated patients.

The company's products have demonstrated exceptional gross profit margins of 94%. Analysts predict sales growth in the current year. BridgeBio's second-quarter 2026 revenue of $243.7 million exceeded consensus estimates of $221 million, with U.S. Attruby net product revenue reaching $222.4 million.